Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study.

Autor:	Dazzan P; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK., Lawrence AJ; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK., Reinders AATS; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK., Egerton A; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., van Haren NEM; Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands.; Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands., Merritt K; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Barker GJ; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Perez-Iglesias R; Early Intervention in Psychosis Service, Department of Psychiatry, Hospital Universitario Marques de Valdecilla, Santander, Spain., Sendt KV; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Demjaha A; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Nam KW; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Sommer IE; Department of Biomedical Sciences of Cells and Systems, Rijksuniversiteit Groningen, University Medical Center Groningen, Groningen, The Netherlands., Pantelis C; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia., Wolfgang Fleischhacker W; Medical University of Innsbruck, Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Innsbruck, Austria., van Rossum IW; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Galderisi S; Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy., Mucci A; Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy., Drake R; Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.; Greater Manchester Mental Health Foundation Trust, Manchester, UK.; Manchester Academic Health Sciences Centre, Manchester, UK., Lewis S; Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.; Greater Manchester Mental Health Foundation Trust, Manchester, UK.; Manchester Academic Health Sciences Centre, Manchester, UK., Weiser M; Department of Psychiatry, Sheba Medical Center, Tel Aviv, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Martinez Diaz-Caneja CM; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain., Janssen J; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain., Diaz-Marsa M; Department of Psychiatry, Instituto de Investigación Sanitaria Hospital Clínico San Carlos; CIBERSAM; Universidad Complutense Madrid, Madrid, Spain., Rodríguez-Jimenez R; Department of Psychiatry, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12); CIBERSAM; Universidad Complutense Madrid, Madrid, Spain., Arango C; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense Madrid, Madrid, Spain., Baandrup L; Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Broberg B; Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Rostrup E; Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Ebdrup BH; Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Glenthøj B; Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Kahn RS; Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA., McGuire P; National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Jazyk:	angličtina
Zdroj:	Schizophrenia bulletin [Schizophr Bull] 2021 Mar 16; Vol. 47 (2), pp. 444-455.
DOI:	10.1093/schbul/sbaa115
Abstrakt:	Individuals with psychoses have brain alterations, particularly in frontal and temporal cortices, that may be particularly prominent, already at illness onset, in those more likely to have poorer symptom remission following treatment with the first antipsychotic. The identification of strong neuroanatomical markers of symptom remission could thus facilitate stratification and individualized treatment of patients with schizophrenia. We used magnetic resonance imaging at baseline to examine brain regional and network correlates of subsequent symptomatic remission in 167 medication-naïve or minimally treated patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder entering a three-phase trial, at seven sites. Patients in remission at the end of each phase were randomized to treatment as usual, with or without an adjunctive psycho-social intervention for medication adherence. The final follow-up visit was at 74 weeks. A total of 108 patients (70%) were in remission at Week 4, 85 (55%) at Week 22, and 97 (63%) at Week 74. We found no baseline regional differences in volumes, cortical thickness, surface area, or local gyrification between patients who did or did not achieved remission at any time point. However, patients not in remission at Week 74, at baseline showed reduced structural connectivity across frontal, anterior cingulate, and insular cortices. A similar pattern was evident in patients not in remission at Week 4 and Week 22, although not significantly. Lack of symptom remission in first-episode psychosis is not associated with regional brain alterations at illness onset. Instead, when the illness becomes a stable entity, its association with the altered organization of cortical gyrification becomes more defined. (© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu